GVN Healthcare & Pharma Centers of Excellence Coalition
GVN Healthcare & Pharma Centers of Excellence
The business community is an integral partner in stemming the spread of viral diseases worldwide. Viral outbreaks, such as SARS-CoV-2 / COVID19, know no boundaries and spread rapidly beyond national borders, accompanied by panic, uncertainty, and losses to workforces, productivity and revenue streams. Multinational corporations and businesses with international interests are vital partners in preparations against current and future potential pandemics and in stopping the spread of viruses.
The main goal of the GVN Healthcare & Pharma Centers of Excellence Coalition is to link the business community with leading medical virologists, support cutting edge viral research, drug and vaccine development and training activities, increase awareness of medical virology issues and serve as a platform for partnerships to strengthen international viral preparedness and response.
As part of the GHPC, participating corporations will be incorporated as a “GVN Healthcare & Pharma Center of Excellence”. This will allow access and cooperation with GVN Academic Centers of Excellence to the mutual benefit of the GVN and GVN Healthcare & Pharma Centers of Excellence Coalition.
This mutually beneficial partnership includes:
- Research Collaboration
- Training Future Virologists
- New Strategic Partners
- Visibility and Impact
- Attendance at the annual and reginal GVN meetings.
- Outbreak Notification, Evaluation & Response Briefings.
If you are interested in joining the coalition, please contact Linman Li, Vice President of the GVN, at [email protected].
For nearly three decades Abbott has monitored HIV and hepatitis viruses and identified mutations which help ensure the company’s diagnostic tests remain up to date through its Global Surveillance Program. The surveillance program continues to be a pathway fueled by collaboration, enabling researchers to proactively evaluate and solve infectious disease challenges. In partnership with institutions around the world, the program has collected more than 78,000 samples containing HIV and hepatitis viruses, identified and characterized thousands of strains, and published 143 research papers to date to help the scientific community learn more about viruses and mutations. Most recently the company unveiled the Abbott Pandemic Defense Coalition – a first-of-its-kind global scientific and public health partnership dedicated to the early detection of — and rapid response to — future pandemic threats.
1) Michael G. Berg, Ana Olivo, Barbara J. Harris, Mary A. Rodgers, Linda James, Samuel Mampunza, Jonathon Niles, Franklin Baer, Julie Yamaguchi, Lazare Kaptue, Oliver Laeyendecker, Tom Quinn, Carole McArthur, Gavin A. Cloherty. A high prevalence of potential elite HIV viral controllers identified over 30 years in Democratic Republic of Congo. eBiomedicine.
2) Berg MG, Olivo A, Forberg K, Harris BJ, Yamaguchi J, Shirazi R, Gozlan Y, Sauleda S, Kaptue L, Rodgers MA, Mor O, Cloherty GA. Advanced molecular surveillance approaches for characterization of blood borne hepatitis viruses. PLoS One (2020) Jul 17;15(7):e0236046.
3) Yamaguchi J, McArthur C, Vallari A, Sthreshley L, Cloherty GA, Berg MG, Rodgers MA. Complete genome sequence of CG-0018a-01 establishes HIV-1 subtype L. JAIDS. (2020) Mar 1;83(3):319-322. PMID 31693506.
Follow Abbott on Twitter: @AbbottNews
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life